跳到正文
WHO 药品预认证与检查动态·· 20 天前AI 评分43

WHO 将 Cipla 的 Nirmatrelvir+Ritonavir 与 Getz 的莫西沙星片剂列入预认证清单

Cipla’s Nirmatrelvir + Ritonavir and Getz’s Moxifloxacin tablet products prequalified

AI 导读

WHO 预认证小组将 Cipla(印度)的 Nirmatrelvir 150 mg 与 Ritonavir 100 mg 共泡罩片(CV028)和 Getz Pharma(巴基斯坦)的莫西沙星(盐酸盐)400 mg 片(TB418)列入预认证清单。前者用于治疗有进展为重症风险的轻症 COVID-19 患者,后者与其他抗结核药物联用治疗结核病,包括耐药结核方案。

正文 · 原文

News

3 November, 2026 - 00:12 (CET)

Announcement

WHO Prequalification Unit (PQT) added the below new products to its prequalified list:

  • CV028  Nirmatrelvir 150 mg and Ritonavir 100 mg Co-blistered tablets – Cipla, India 
  • TB418  Moxifloxacin (as hydrochloride) 400mg tablet – Getz Pharma, Pakistan 

Nirmatrelvir 150 mg and Ritonavir 100 mg Co-blistered tablets product is indicated for the treatment of coronavirus disease 2019 (COVID-19) in patients with non-severe disease whose disease is at higher risk for progressing to severe COVID-19.

Moxifloxacin (as hydrochloride) 400mg tablet is indicated in combination with other tuberculosis medicines for the treatment of tuberculosis due to Mycobacterium tuberculosis including in regimens for drug-resistant tuberculosis.
 

来源:WHO 药品预认证与检查动态 · extranet.who.int